“…Longer follow-up, focused on the stability of CR for years after infusion, is beginning to be reported and provides both reason for celebration and also a mandate for further optimization of these therapeutics. 138,144,152,173 Thus, recent work from multiple centers in the United States and China have documented high CR rates as well as sustained remissions in patients treated with CD19-CAR-T cells, both with and without additional consolidation, 108,111,[136][137][138][144][145][146][147][148][149][150][151][152][153][154][155]173 striking results given the high-risk patient populations that have been treated. However, it is now clear that for most patients, the CR is not followed by long-term remission, with more than half of patients ultimately relapsing following CAR-T therapy.…”